Pegvisomant Investigated to Reduce Growth Hormone Excess in McCune-Albright Syndrome Patients
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
Abstract
Pegvisomant is being investigated in a 36-week clinical trial to reduce IGF-1 levels and mitigate growth hormone excess effects in McCune-Albright Syndrome patients.